Whether future clinical trials would benefit from incorporating consideration of APOE Ɛ4 genotype, or other genetic markers associated with Alzheimer’s disease, into the study design remains to be determined. The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.